Skip to Main Content
Skip Nav Destination

Call for Editor-in-Chief Nominations


ASH Seeks Editors-in-Chief for Three Journals

 

General Application Information 

  • ASH members may self-nominate for any position by submitting a cover letter, CV, brief description of previous editorial experience, and vision statement for the journal.
  • Nominations from international members are encouraged.
  • Members are also welcome to nominate a colleague by submitting a brief informal endorsement. ASH will confirm the nominee’s membership status and request the submission of additional materials to complete the nomination.
  • ASH prohibits members employed by a pharmaceutical or biomedical company from serving in an editorial position.
  • Email all nominations to editorsearch@hematology.org. Subject line must include the publication name.
    • Blood Journals by 11:59 PM EDT on June 1, 2024

 

Blood Journals

Blood  is the premier peer-reviewed journal in hematology and the flagship journal of ASH. Published online daily and in print weekly, Blood has provided an international forum for the publication of original articles describing basic laboratory, translational, and clinical investigations in hematology since 1946. The term is five years with the potential for one five-year extension. The editor-in-chief designee transition period begins October 1, 2024. An honorarium is provided.

Blood Erythrocytes is an  open-access, peer-reviewed journal from ASH which offers an international forum for the publication of original articles related to red blood cells. The journal aims to publish original work relevant to hematologic disease involving the erythroid lineage with significant clinical and/or scientific impact, including sickle cell disease, thalassemia, malaria, anemias (inherited and acquired, nutritional, and immune-mediated), and normal and ineffective erythropoiesis (including myelodysplasia). The term is five years with the potential for one five-year extension. The editor-in-chief designee engagement period begins September 1, 2024. An honorarium is provided.

Blood Immunology & Cellular Therapy is an open-access, peer-reviewed journal from ASH which offers an international forum for the publication of original articles related to blood immunology and cellular therapy. The journal aims to publish original work relevant to hematologic disease with significant clinical and/or scientific impact, including immunotherapy and transplantation (including biology). The term is five years with the potential for one five-year extension. The editor-in-chief designee engagement period begins September 1, 2024. An honorarium is provided.

Candidate Qualifications:

  • Must have significant editorial experience, preferably as an editor of a peer-reviewed journal
  • A distinguished research record
  • Broad and comprehensive knowledge of basic, translational, and clinical research
  • A record of leadership in the community
  • Must be an ASH member in good standing
  • MD, MD/PhD, or equivalent degree
  • An interest in developing innovative new content
  • Knowledge of ASH programs and initiatives
  • Experience coordinating international collaborations
  • Familiarity with international experts in the field to solicit relevant, high-quality articles

Email nominations by 11:59 PM EDT June 1, 2024

 

Close Modal

or Create an Account

Close Modal
Close Modal